Survival benefit for patients with metastatic urothelial carcinoma receiving continuous maintenance chemotherapy

Chuang Chi Liaw*, Tzu Yao Liao, Ke Hung Tsui, Yu Hsiang Juan

*此作品的通信作者

研究成果: 期刊稿件文章同行評審

5 引文 斯高帕斯(Scopus)

摘要

Background/Aim: Urothelial carcinoma is a chemo-sensitive cancer. We investigated the contributory factors to survival benefit of metastatic urothelial carcinoma (MUC) patients receiving continuous maintenance chemotherapy. Patients and Methods: Inclusion criteria were: i) pathology-confirmed urothelial carcinoma, ii) metastatic lesions identified mainly on pre-therapy computed tomography (CT) scans, and iii) inpatient-administered chemotherapy of at least three cycles. Chemotherapy regimens included 5-fluorouracil, leucovorin, cisplatin, and gemcitabine. Results: A total of 139 cases were enrolled in this study. The overall objective response rate was 60% and the median survival time was 17 months. Eight-two (59%) patients had inflammation-related symptoms following the course of chemotherapy. Fifty-five (41%) patients survived more than two years. All patients exhibited various fibrosis formations. No patient experienced unfavorable metastatic conditions. Inflammation-related symptoms remained in 28 (51%) patients. We found that surgery, invasive procedures, and infection likely led to a rapid tumor progression. Conclusion: Continuous maintenance chemotherapy targeting chemo-sensitive tumors, administered at metronomic intervals and focus on tumor microenvironment, can increase MUC survival benefits.

原文英語
頁(從 - 到)1249-1262
頁數14
期刊In Vivo
33
發行號4
DOIs
出版狀態已出版 - 2019
對外發佈

文獻附註

Publisher Copyright:
© 2019 International Institute of Anticancer Research. All rights reserved.

指紋

深入研究「Survival benefit for patients with metastatic urothelial carcinoma receiving continuous maintenance chemotherapy」主題。共同形成了獨特的指紋。

引用此